Form 4: Atara Biotherapeutics Director Receives Equity Grant

Director Matthew K. Fust was granted 12,000 restricted stock units in Atara Biotherapeutics, Inc.

Summary

• Director Matthew K. Fust acquired 12,000 restricted stock units (RSUs) of Atara Biotherapeutics, Inc. common stock.
• The transaction occurred on June 9, 2026.
• The RSUs were granted at a price of $0 per share.
• Following this transaction, the reporting person's total beneficial ownership is 30,188 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified.

Risks

• Vesting of the units is subject to the reporting person's continuous service to the company.

Future Outlook

The restricted stock units are scheduled to vest on the earlier of June 9, 2027, or the date of the next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure long-term alignment with shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units to directors is consistent with standard compensation practices for publicly traded biopharmaceutical companies.

Stakeholder Impact

• Minor dilution impact to existing shareholders upon the eventual vesting and issuance of shares.

Next Steps

• Vesting of the 12,000 restricted stock units on June 9, 2027, or the next annual meeting.

Key Dates

Keywords

Atara Biotherapeutics, ATRA, Form 4, Insider Transaction, Equity Grant, Director Compensation